HELICAL-FUSION
Helical Fusion has entered a partnership agreement with the National Institute for Fusion Science (NIFS) in March 2024. NIFS has established the "HF Collaboration Research Group" with activities starting in April, special experimental research space has been dedicated onsite at NIFS, which already houses the world's largest superconductor and fusion experimental facility, for Helical Fusion.
With its support from NIFS, Helical Fusion will accelerate the realization of the world's first commercial fusion reactor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507957768/en/
Co-Founder, CEO of Helical Fusion Takaya Taguchi (left) and Chief of Industry-Academia-Government Coordination Section of NIFS Ryo Yasuhara (right), shake hands at NIFS in Toki-City, Gifu, Japan. (Photo: Business Wire)
[Background]
Against the backdrop of a projected global population increase of ~1.7 billion by 2050* and the corresponding surge in worldwide electricity demand, conventional power generation methods alone are expected to struggle to meet these needs. Fusion power offers a clean and safe alternative, utilizing inexhaustible fuel supplies, such as seawater, and thus holds the promise as a technology capable of fundamentally addressing these global challenges. With Japan's energy self-sufficiency rate at a low of 13.3% and fossil fuel dependency still exceeding 80%**, research and development efforts have been underway to secure future baseload power sources.
NIFS, boasting one of the world's largest fusion experimental facilities, the Large Helical Device (LHD) in Gifu prefecture, Japan, has been at the forefront of research into helical-type fusion reactors since its establishment by the government in 1989, yielding remarkable results on a global scale. Building on NIFS's expertise, Helical Fusion was founded in 2021, leveraging the speed and agility typical of startups to lead the development of the world's first commercial steady fusion reactor.
While individual collaborative research efforts have been ongoing with NIFS, the firm establishment of the "HF Collaboration Research Group" going forward, as well as a dedicated experimental space, marks a significant step toward strengthening cooperation, aimed towards the early social implementation of fusion energy.
Reference: for the press release from the National Institute for Fusion Science, click here)
[Comment from Mr. Takaya TAGUCHI (Co-founder, CEO of Helical Fusion)]
Helical Fusion is a startup born from the wealth of cutting-edge research achievements and expertise accumulated by NIFS over more than 30 years. We have conducted numerous joint research projects with NIFS in areas such as high-temperature superconducting magnets and liquid metal blankets. Given the growing global expectations of the helical-stellarator fusion approach, to operate as a steady-state commercialized reactor, we have further strengthened our collaboration to accelerate development by establishing this department, as well as setting up dedicated experimental research space. This will not only accelerate joint research but also advance progress in our proprietary tech development, particularly in the field of high-temperature superconducting magnets. We express our feelings of appreciation to the NIFS team for their cooperation and strive to meet everyone's expectations by furthering our efforts in research and development, so as to lead development with global competition towards an operation ready, steady-state fusion reactor. Furthermore, we aim to contribute to the creation of industries where Japan's proud technologies, from basic research to high-end manufacturing, can be leveraged.
[Comment from Mr. Ryo Yasuhara (Chief of Industry-Academia-Government Coordination Section, NIFS)]
The National Institute for Fusion Science has established a collaborative research department with Helical Fusion, called the "HF Collaboration Research Group", in order to conduct research and development for the practical implementation of helical-type fusion reactors. This joint research group will mainly contribute the specialized knowledge and resources of Helical Fusion and NIFS to conduct research activities aimed at realizing helical-type fusion reactor. NIFS aims to contribute to the advancement of fusion science and the establishment of a broad foundation for science and technology through research activities at the highest global standards. We hope that the achievements obtained in this research group will be a step towards realizing sustainable energy.
*“World Energy Outlook 2023” International Energy Agency (https://www.iea.org/reports/world-energy-outlook-2023)
**”The white paper on energy usage 2022”, Agency for Natural Resources and Energy (https://www.enecho.meti.go.jp/about/whitepaper/2023/pdf/)
[About Us]
Helical Fusion is a Japanese start-up company aiming at the social implementation of fusion energy with a magnetic confinement fusion reactor.
Various fusion methods have been developed in the world over the past 60 years as a next generation energy source.
In Japan, the helical fusion method, which uses a superconducting helical coil with a double-helical structure similar to DNA to stably confine high-temperature plasma, has been developed and nurtured to a great extent. We are aiming to develop the world's first steady-state fusion reactor by incorporating more advanced technologies into the helical-stellarator type fusion reactor.
Additionally, Helical Fusion's proprietary development efforts, including high-temperature superconducting magnet vital for realizing commercial reactors, have received Japanese SBIR grant funding, further accelerating progress towards commercialization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507957768/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
